Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

NASDAQ:AGRX opened at $1.51 on Friday. Agile Therapeutics has a 12-month low of $0.20 and a 12-month high of $2.63. The firm has a market cap of $10.35 million, a PE ratio of -0.41 and a beta of 1.58. The stock has a fifty day moving average price of $1.48 and a 200 day moving average price of $0.89.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter. The firm had revenue of $5.58 million during the quarter.

Institutional Investors Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC raised its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.